Novel Resorcinol Dibenzyl Ether-Based PD-L1 Inhibitors Modulate Lipid Metabolism for Enhanced Tumor Immunotherapy
- 8 March 2026
- journal article
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 69 (6) , 6546-6568
Abstract
No abstract availableFunding Information
- National Natural Science Foundation of China (82173668)
- National Natural Science Foundation of China (82373706)
This publication has 47 references indexed in Scilit:
- Targeted protein degradation with small molecules for cancer immunotherapyAsian Journal of Pharmaceutical Sciences, 2025
- Targeting lipid metabolism in regulatory T cells for enhancing cancer immunotherapyBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2025
- Phytochemicals in regulating PD‐1/PD‐L1 and immune checkpoint blockade therapyPhytotherapy Research, 2023
- Understanding immune checkpoints and PD-1/PD-L1-mediated immune resistance towards tumour immunotherapy3 Biotech, 2023
- Small molecule-based immunomodulators for cancer therapyActa Pharmaceutica Sinica B, 2022
- Recent advances in the clinical development of immune checkpoint blockade therapyCellular Oncology, 2019
- In vitro assay for the development of small molecule inhibitors targeting PD-1/PD-L12019
- Improved side‐chain torsion potentials for the Amber ff99SB protein force fieldProteins: Structure, Function, and Bioinformatics, 2010
- Development and testing of a general amber force fieldJournal of Computational Chemistry, 2004
- Numerical integration of the cartesian equations of motion of a system with constraints: molecular dynamics of n-alkanesJournal of Computational Physics, 1977